Effect of Tertiary A-level Hospital Remote Intervention on MACCE, Adherence to Drugs and Risk Factors Control in Patients With Stable Coronary Artery Disease Compared With Traditional Community Hospital Follow-up — CHIPCHAT

Acute Coronary Syndrome Clinical Trial

Official title:
Effect of Tertiary A-level Hospital Remote Intervention on MACCE, Adherence to Drugs and Risk Factors Control in Patients With Stable Coronary Artery Disease Compared With Traditional Community Hospital Follow-up

Status Completed

Clinical Trial Summary

The study was a multicenter, two-arm, parallel, open label, prospective study intended for to compare effect of offline community hospital intervention on adherence to drugs and risk factors control in patients with stable coronary artery disease compared with tertiary A-level hospital WeChat-based intervention.

Clinical Trial Description

Objective: This study is intended for to compare effect of offline community hospital intervention on adherence to drugs and risk factors control in patients with stable coronary artery disease compared with tertiary A-level hospital WeChat-based intervention. Study design: The study was a multicenter, two-arm, parallel, open label, prospective study that evaluated a WeChat-based intervention offered by tertiary A-level hospital with 1 year of follow-up. Study intervention: All patients received lifestyle intervention and drug adjustment at 1 month, 3 months, 6 months and 1 year follow-up. In the control group, the subsequent visit was through an offline outpatient clinic at 4 different community hospitals. Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention. While in the intervention group, the subsequent visit was through WeChat-based online consultations. Outcome measures: The primary outcome was MACCE. Secondary outcome included blood pressure, heart rates, smoking cessation, drinking cessation, body mass index, and medications adherence. Statistical analysis: Values of analyzed endpoints between intervention group and control group will be compared according to the analysis plan. We'll follow a prespecified analysis plan and subgroup analysis will be conducted accordingly. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04795505
Study type	Observational
Source	Chinese Academy of Medical Sciences, Fuwai Hospital
Contact
Status	Completed
Phase
Start date	September 1, 2018
Completion date	January 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06013813` - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI	N/A
Recruiting	`NCT05846893` - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease	N/A
Recruiting	`NCT05412927` - AngelMed Guardian® System PMA Post Approval Study
Completed	`NCT02750579` - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?	N/A
Completed	`NCT04102410` - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients	N/A
Enrolling by invitation	`NCT03342131` - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome	N/A
Recruiting	`NCT01218776` - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation	`NCT04676100` - International CR Registry
Completed	`NCT03590535` - 5th Generation cTnT in ED ACS
Recruiting	`NCT05437900` - INSIGHTFUL-FFR Clinical Trial	Phase 4
Completed	`NCT05551429` - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated	`NCT04316481` - IDE-ALERTS Continued Access Study	N/A
Active, not recruiting	`NCT04475380` - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting	`NCT04852146` - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting	`NCT02892903` - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?	N/A
Completed	`NCT04077229` - Piloting Text Messages to Promote Positive Affect and Physical Activity	N/A
Not yet recruiting	`NCT02871622` - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM	N/A
Completed	`NCT02944123` - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)	Phase 3
Active, not recruiting	`NCT02922140` - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit	N/A
Terminated	`NCT02620202` - Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.